Organogenesis/$ORGO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Organogenesis

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.

Ticker

$ORGO
Sector
Primary listing

Employees

869

Organogenesis Metrics

BasicAdvanced
$533M
-
-$0.12
1.77
-

What the Analysts think about Organogenesis

Analyst ratings (Buy, Hold, Sell) for Organogenesis stock.

Bulls say / Bears say

Surgical & Sports Medicine product revenue grew 16% year-over-year to $8.1 million in Q2 2025, demonstrating successful diversification into higher-margin segments.
Net loss narrowed to $9.4 million in Q2 2025 from $17.0 million in Q2 2024, reflecting improved operational leverage and cost management.
As of March 31, 2025, the company held $110.5 million in cash with no debt, providing ample runway for R&D investment and pipeline advancement
Total net product revenue for Q2 2025 fell 23% year-over-year to $100.8 million, underscoring persistent volume pressures in the core business.
Advanced Wound Care net product revenue declined 25% to $92.7 million in Q2 2025, reflecting ongoing reimbursement headwinds and market disruption.
Adjusted EBITDA swung to a loss of $3.6 million in Q2 2025, down from income of $15.6 million a year earlier, highlighting margin compression
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.

Organogenesis Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Organogenesis Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ORGO

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs